Overview

A Bioequivalence Study of Capecitabine Tablets

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2. Experimental Design： Two-period crossover design 3. Test drug: Capecitabine tablets Reference drug: XELODA 4. Sample size：24

Phase:

Phase 1

Details

Lead Sponsor:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd

Treatments:

Capecitabine